Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024;31(33):5351-5369.
doi: 10.2174/0929867330666230515112245.

Radiotherapy-associated Sensorineural Hearing Loss in Pediatric Oncology Patients

Affiliations
Review

Radiotherapy-associated Sensorineural Hearing Loss in Pediatric Oncology Patients

Muhammad Ammar Aslam et al. Curr Med Chem. 2024.

Abstract

During the radiotherapeutic treatment of pediatric oncology patients, they would be at a latent risk of developing ionizing radiation-induced ototoxicity when the cochlea or auditory nerve is located within the radiation field. Sensorineural hearing loss (SNHL) is an irreversible late complication of radiotherapy, and its incidence depends on various factors such as the patient's hearing sensitivity, total radiation dose to the cochlea, radiotherapy fractionation regimen, age and chemoradiation. Importantly, this complication exhibits serious challenges to adult survivors of childhood cancer, as it has been linked to impairments in academic achievement, psychosocial development, independent living skills, and employment in the survivor population. Therefore, early detection and proper management can alleviate academic, speech, language, social, and psychological morbidity arising from hearing deficits. In the present review, we have addressed issues such as underlying mechanisms of radiation-induced SNHL, audiometric findings of pediatric cancer patients treated with radiotherapy, and management and protection measures against radiation-induced ototoxicity.

Keywords: Pediatric cancer; chemoradiation; childhood cancer.; ototoxicity; radiotherapy; sensorineural hearing loss.

PubMed Disclaimer

References

    1. Mortezaee K.; Narmani A.; Salehi M.; Bagheri H.; Farhood B.; Haghi-Aminjan H.; Najafi M.; Synergic effects of nanoparticles-mediated hyperthermia in radiotherapy/chemotherapy of cancer. Life Sci 2021,269,119020 - DOI - PubMed
    1. Abdi Goushbolagh N.; Farhood B.; Astani A.; Nikfarjam A.; Kalantari M.; Zare M.H.; Quantitative cytotoxicity, cellular uptake and radioprotection effect of cerium oxide nanoparticles in MRC-5 normal cells and MCF-7 cancerous cells. Bionanoscience 2018,8(3),769-777 - DOI
    1. Abdi Goushbolagh N.; Keshavarz M.; Zare M.H.; Bahreyni-Toosi M.H.; Kargar M.; Farhood B.; Photosensitizer effects of MWCNTs-COOH particles on CT26 fibroblastic cells exposed to laser irradiation. Artif Cells Nanomed Biotechnol 2019,47(1),1326-1334 - DOI - PubMed
    1. Ford E.C.; Terezakis S.; How safe is safe? Risk in radiotherapy. Int J Radiat Oncol Biol Phys 2010,78(2),321-322 - DOI - PubMed
    1. Baskar R.; Lee K.A.; Yeo R.; Yeoh K.W.; Cancer and radiation therapy: Current advances and future directions. Int J Med Sci 2012,9(3),193-199 - DOI - PubMed